Intellia, Gene Editing
Digest more
A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...
In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...
A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...
Stocktwits on MSN
NTLA stock surges 35% overnight: Retail mood peaks ahead of first-ever phase 3 readout for gene-editing therapy
The Haelo Phase 3 trial marks the first late-stage test of an in-vivo CRISPR gene-editing treatment. ・Earlier mid-stage studies showed a 96% reduction in monthly attack rates, with 97% of patients ...
Topline results from the pivotal HAELO trial demonstrate that a single infusion of lonvo-z significantly reduces HAE attacks and the need for chronic prophylactic therapy.
As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data ...
Researchers from Wageningen University & Research and Van Andel Institute used a variant of CRISPR, a gene-editing tool, to ...
With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...
Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results